Ziprasidone

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Ziprasidone

Examples of brand names: Zeldox [DE]

ATC code: N05AE04

Main use (for orientation): Schizophrenia

Documented research summary

No direct finding for the pair. A treatment comparison in cannabis use disorder establishes neither an interaction nor its absence.

Uncertainties and limitations

Does not establish safety for less-studied cannabinoids or untested formulations/doses.

Do not infer clinical dosage from preclinical effects or enzyme hypotheses.

Research is limited to the specified date and protocol; it is not globally exhaustive. Brand names and authorisations do not constitute a complete current market overview.

Structured assessment

Category: Drug context

Cannabinoid scope: 28 register names in the documented search family; neither 28 individual clinical trials nor a blanket assessment of all cannabinoids.

Evidence status: Insufficient pair-specific data

Mechanism / drug context: Ziprasidone: predominantly non-CYP breakdown, CYP3A4 contribution and QT relevance.

Type of supporting material: Medicine information and documented individual review; no positive pair trial

Clinical interpretation: Requires individual assessment by a doctor or pharmacist. Lack of evidence does not establish safety; no dosage or discontinuation advice is provided.

Context: Oral ziprasidone hydrochloride capsules, US; schizophrenia and bipolar indications. Intramuscular mesylate identified as a different formulation. D2/5-HT2 antagonistic activity; separate QT-prolongation warning, additive CNS effects and hypotension as possible pharmacodynamic interactions.

Drug context and gaps in search results are not measured interactions. The source role below describes which statement the source actually supports.

Source role [C_LABEL_D0127_ORAL]: Drug context

Statement supported: Supports dosage form, metabolism and/or known risks; alone, it does not substantiate a cannabinoid–drug pair finding.

Source: Ziprasidone hydrochloride capsules [Remedyrepack] [C_LABEL_D0127_ORAL]

Source role [C_PR_24628830]: Scope distinction / context

Statement supported: Ziprasidone/clozapine treatment comparison, not isolated cannabinoid pharmacokinetics.

Source: Ziprasidone versus clozapine in the treatment of dually diagnosed (DD) patients with schizophrenia and cannabis use disorders: a randomized study. [C_PR_24628830]

Scope of review: Individual research with documented title/abstract screening and targeted review of original sections. This is not exhaustive evidence that interactions are absent.

Unresolved source question: The complete stored individual review, label review, literature screening, conclusion and uncertainties were read. Targeted sections of original information were rechecked; no claim is made that all product information or full texts were completely revalidated.

Separately recorded findings

No separately substantiated finding for this drug–cannabinoid pair is recorded within the documented scope of review. This does not prove that no such study exists anywhere or that the combination is safe.

References and access status

[C_LABEL_D0127_ORAL] Ziprasidone hydrochloride capsules [Remedyrepack]

Original source / bibliographic reference

Authors: Remedyrepack Inc.

Year: 2026

Source type: US SPL

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[C_PR_24628830] Ziprasidone versus clozapine in the treatment of dually diagnosed (DD) patients with schizophrenia and cannabis use disorders: a randomized study.

Original source / bibliographic reference

Authors: Schnell T, Koethe D, Krasnianski A, Gairing S, Schnell K, Daumann J, Gouzoulis-Mayfrank E.

Year: 2014

Source type: Primary source, abstract read

DOI: 10.1111/j.1521-0391.2014.12126.x

PMID: 24628830

Source access – 23 October 2026: Direct retrieval could not be fully verified; availability remains unresolved.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility